Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
NCT ID: NCT05438498
Last Updated: 2023-09-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE3
Total Enrollment
550 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-06-03
Study Completion Date
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If a treated cancer patient cannot make antibodies to a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Emergency Use Authorization (EUA) or approved vaccine, their risk for infection and its sequelae are significantly increased. The Astra-Zeneca Immuno-Suppressed Program (AISP) is designed to address whether a patient treated for cancer who receives a single-dose of Evusheld (AZD7442) 600 mg IM or IV will maintain a stable/protective effect against symptomatic SARS-CoV-2 infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death up to 12 months post-baseline. The program will focus on patients with cancer who have been treated with chemotherapy, immunotherapy, targeted therapy, other therapy or combination therapy with or without radiation therapy within 12 months prior to enrollment, are willing/able to receive one IM or IV injection of Evusheld, are able to complete 14 Patient Experience/Clinical Outcome Assessment (COA) surveys, 6 Quality of Life (QoL) assessments and are willing to allow serum concentrations of Evusheld to be drawn 9 times, 3 SARS-CoV-2 Receptor Binding Domain-Immunoglobulin G (RBD-IgG) tests, and T-cell assay to be drawn once. In the event of a symptomatic break-thru SARS-CoV-2 positive infection by SARS-COV-2 Ribonucleic Acid (RNA) by Reverse Transcription Polymerase Chain Reaction (RT-PCR) test, the patient will have an additional Evusheld serum concentration, SARS-CoV-2 RBD-IgG antibody level and T-cell assay obtained in a temporally related manner. The program requires treatment with Evusheld 600 mg IM or IV.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
NCT05569408
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
COMPLETED
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
NCT05375760
Coronavirus Disease 2019 (COVID-19)
TERMINATED
PHASE2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
NCT06057064
COVID-19, SARS-CoV-2
COMPLETED
PHASE2
Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China
NCT05917951
COVID-19
COMPLETED
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
NCT04952402
Covid19
SARS-CoV2 Infection
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to quantify the serum concentration of Evusheld (AZD7442) at 1, 2, 3, 4, 5, 6, 7, 9 or 12-months post-baseline in all qualified cancer patients treated with a single-dose of Evusheld 600 mg IM or IV at baseline.
The secondary objectives of the study are as follows:
* Compare the incidence of symptomatic Sudden Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death between solid tumor and hematologic malignancy patients.
* Compare of the incidence of symptomatic SARS-CoV-2 infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death between patients treated with chemotherapy only, immunotherapy only, targeted therapy only or other/combination therapy only over 12 months post-baseline.
* Compare the serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline between solid tumor and hematologic malignancy patients.
* Compare the serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline between patients treated with chemotherapy only, immunotherapy only, targeted therapy only or other/combination therapy only.
* Compare of the incidence of symptomatic SARS-CoV-2 infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death to the levels of serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline in all patients.
* Compare the incidence of severe SARS-CoV-2 (pneumonia or hypoxemia and World Health Organization (WHO) score of ≥5) based on the TACKLE study definition between solid tumor and hematologic malignancy patients.
* Compare the incidence of severe SARS-CoV-2 (pneumonia or hypoxemia, and WHO score of ≥5) based on the TACKLE study definition death between patients treated with chemotherapy only, immunotherapy only, targeted therapy only or other/combination therapy only over 12 months post-baseline.
* Compare the incidence of severe SARS-CoV-2 (pneumonia or hypoxemia, and WHO score of ≥5) based on the TACKLE study definition to the levels of serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline in all patients.
* Compare time to first event e.g., SARS-COV-2 RNA by Reverse Transcription Polymerase Chain Reaction (RT-PCR) positivity, symptomatic SARS-CoV-2 infection, hospitalization, and/or death between all four strata
* Compare Quality-of-Life metrics in all cancer patients, as measured by change from baseline to days 2, 90, 180, 270, and 360 post-baseline, and then compare the same Quality-of-Life metrics at each timepoint between each of the four strata
* Assess patient safety and adverse events including medically attended visits, Emergency Room/Urgent Care/Telehealth visits using Patient Experience/Clinical Outcome Assessment (COA) survey data for patients in each of the four strata
* Evaluate whether solid tumor or hematologic malignancy patients have a greater incidence of Evusheld-related side effects
* Assess the use of Machine Learning to predict the incidence of SARS-CoV-2 infection at days 30, 60, 90, 120, 150, 180, 210, 270 and 360 post-baseline in all cancer patients based on serum Evusheld concentration levels 3.3.3 Exploratory Objectives:
* Virologic surveillance to detect all SARS-CoV-2 variants occurring during the study in patients that test positive for SARS-CoV-2 by SARS-COV-2 RNA by Reverse Transcription Polymerase Chain Reaction (RT-PCR) testing
* Detection of potential new variants identified by positive SARS-COV-2 RNA by RT-PCR testing
The secondary objectives of the study are as follows:
* Compare the incidence of symptomatic Sudden Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death between solid tumor and hematologic malignancy patients.
* Compare of the incidence of symptomatic SARS-CoV-2 infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death between patients treated with chemotherapy only, immunotherapy only, targeted therapy only or other/combination therapy only over 12 months post-baseline.
* Compare the serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline between solid tumor and hematologic malignancy patients.
* Compare the serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline between patients treated with chemotherapy only, immunotherapy only, targeted therapy only or other/combination therapy only.
* Compare of the incidence of symptomatic SARS-CoV-2 infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death to the levels of serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline in all patients.
* Compare the incidence of severe SARS-CoV-2 (pneumonia or hypoxemia and World Health Organization (WHO) score of ≥5) based on the TACKLE study definition between solid tumor and hematologic malignancy patients.
* Compare the incidence of severe SARS-CoV-2 (pneumonia or hypoxemia, and WHO score of ≥5) based on the TACKLE study definition death between patients treated with chemotherapy only, immunotherapy only, targeted therapy only or other/combination therapy only over 12 months post-baseline.
* Compare the incidence of severe SARS-CoV-2 (pneumonia or hypoxemia, and WHO score of ≥5) based on the TACKLE study definition to the levels of serum concentration of Evusheld at 1, 2, 3, 4, 5, 6, 7, 9 and 12-months post-baseline in all patients.
* Compare time to first event e.g., SARS-COV-2 RNA by Reverse Transcription Polymerase Chain Reaction (RT-PCR) positivity, symptomatic SARS-CoV-2 infection, hospitalization, and/or death between all four strata
* Compare Quality-of-Life metrics in all cancer patients, as measured by change from baseline to days 2, 90, 180, 270, and 360 post-baseline, and then compare the same Quality-of-Life metrics at each timepoint between each of the four strata
* Assess patient safety and adverse events including medically attended visits, Emergency Room/Urgent Care/Telehealth visits using Patient Experience/Clinical Outcome Assessment (COA) survey data for patients in each of the four strata
* Evaluate whether solid tumor or hematologic malignancy patients have a greater incidence of Evusheld-related side effects
* Assess the use of Machine Learning to predict the incidence of SARS-CoV-2 infection at days 30, 60, 90, 120, 150, 180, 210, 270 and 360 post-baseline in all cancer patients based on serum Evusheld concentration levels 3.3.3 Exploratory Objectives:
* Virologic surveillance to detect all SARS-CoV-2 variants occurring during the study in patients that test positive for SARS-CoV-2 by SARS-COV-2 RNA by Reverse Transcription Polymerase Chain Reaction (RT-PCR) testing
* Detection of potential new variants identified by positive SARS-COV-2 RNA by RT-PCR testing
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
SARS-CoV-2 Infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
multi-center, prospective, open-label, pragmatic evaluation
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Evusheld (AZD7442)
Evusheld (tixagevimab+cilgavimab) 600 mg IM or IV administered one time only
Group Type
OTHER
Evusheld (tixagevimab+cilgavimab) IM or IV
Intervention Type
DRUG
Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evusheld (tixagevimab+cilgavimab) IM or IV
Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
AZD7442
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or Female gender at birth
* Age at least 18 years
* Women who are not pregnant, not breast feeding and of child bearing potential using contraception prior to enrollment in the study. Women of child bearing potential must agree to continued use of contraception throughout the 12 months of study participation.
* It is preferable that a patient has access to a "smartphone" or tablet or laptop or desktop computer and/or an email address
* In the event that a patient does not have access to any of the above, the patient may complete all follow-up surveys via the study's Call Center or in written form in the offices of the Principal Investigator as specified in the protocol
* Documented diagnosis of either hematologic malignancy or solid tumor as identified by standard ICD-10 diagnostic category
* Patients may be included with any ONE of the following criteria:
* On active treatment for solid tumor or hematologic malignancies. This can include: high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), as well as any FDA-approved alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) or any combination of these agents
* Hematologic malignancy patients can also be included if he/she is up to 12 months post-treatment and either in remission, stable or progressing as determined by the Investigator
* Solid tumor patients can also be included if he/she is up to 6 months post-treatment
* Received chimeric antigen receptor (CAR-T) or hematopoietic stem cell transplant (within 1 year of transplantation or taking immunosuppression therapy)
* Cancer is progressing as determined by the Investigator
* Treatment must have been initiated ≤12 months prior to baseline for all patients,
* Concomitant radiation therapy is permitted but cannot be the sole therapy
* Have been vaccinated with one or more doses of Janssen, Moderna or Pfizer COVID-19 vaccine
* If having been previously diagnosed with SARS-CoV-2 infection, the diagnosis has to be at least 90 days prior to study randomization. If previously diagnosed, previous treatment with Ivermectin or hydroxychloroquine is acceptable.
* Have a negative SARS-CoV-2 antigen rapid test performed in the office at screening
* Patient willing to receive treatment with AZD7442 600 mg IM or IV
* Patient willing to complete baseline and 13 post-enrollment Patient Experience/Clinical Outcome Assessment surveys.
* Patient willing to complete baseline and 5 QoL assessments
* Patient willing to have blood drawn for serum concentration of AZD7442 9 times post-baseline and repeated if patient becomes COVID-19 positive
* Patient willing to have blood drawn for T-cell assay at day 30 post-baseline and repeated if patient becomes SARS-COV-2 RNA by RT-PCR positive
* Patient willing to have RBD-IgG drawn at baseline, days 90 and 180 post-baseline and repeated if patient becomes SARS-COV-2 RNA by RT-PCR positive
* Patient willing to signed Informed Consent Form
* Patient willing to sign Authorization for Release of Health Information (including treating physicians' or other medical personnel's records, medication prescriber records, pharmacy records and medical insurance claims)
* Age at least 18 years
* Women who are not pregnant, not breast feeding and of child bearing potential using contraception prior to enrollment in the study. Women of child bearing potential must agree to continued use of contraception throughout the 12 months of study participation.
* It is preferable that a patient has access to a "smartphone" or tablet or laptop or desktop computer and/or an email address
* In the event that a patient does not have access to any of the above, the patient may complete all follow-up surveys via the study's Call Center or in written form in the offices of the Principal Investigator as specified in the protocol
* Documented diagnosis of either hematologic malignancy or solid tumor as identified by standard ICD-10 diagnostic category
* Patients may be included with any ONE of the following criteria:
* On active treatment for solid tumor or hematologic malignancies. This can include: high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), as well as any FDA-approved alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) or any combination of these agents
* Hematologic malignancy patients can also be included if he/she is up to 12 months post-treatment and either in remission, stable or progressing as determined by the Investigator
* Solid tumor patients can also be included if he/she is up to 6 months post-treatment
* Received chimeric antigen receptor (CAR-T) or hematopoietic stem cell transplant (within 1 year of transplantation or taking immunosuppression therapy)
* Cancer is progressing as determined by the Investigator
* Treatment must have been initiated ≤12 months prior to baseline for all patients,
* Concomitant radiation therapy is permitted but cannot be the sole therapy
* Have been vaccinated with one or more doses of Janssen, Moderna or Pfizer COVID-19 vaccine
* If having been previously diagnosed with SARS-CoV-2 infection, the diagnosis has to be at least 90 days prior to study randomization. If previously diagnosed, previous treatment with Ivermectin or hydroxychloroquine is acceptable.
* Have a negative SARS-CoV-2 antigen rapid test performed in the office at screening
* Patient willing to receive treatment with AZD7442 600 mg IM or IV
* Patient willing to complete baseline and 13 post-enrollment Patient Experience/Clinical Outcome Assessment surveys.
* Patient willing to complete baseline and 5 QoL assessments
* Patient willing to have blood drawn for serum concentration of AZD7442 9 times post-baseline and repeated if patient becomes COVID-19 positive
* Patient willing to have blood drawn for T-cell assay at day 30 post-baseline and repeated if patient becomes SARS-COV-2 RNA by RT-PCR positive
* Patient willing to have RBD-IgG drawn at baseline, days 90 and 180 post-baseline and repeated if patient becomes SARS-COV-2 RNA by RT-PCR positive
* Patient willing to signed Informed Consent Form
* Patient willing to sign Authorization for Release of Health Information (including treating physicians' or other medical personnel's records, medication prescriber records, pharmacy records and medical insurance claims)
Exclusion Criteria
* Women who are pregnant, breast feeding or of child bearing potential and not using contraception
* Absence of a qualifying type of cancer as defined by standard ICD-10 diagnostic criteria
* Treatment initiated \>12 months prior to baseline or were not on active therapy ≤12 months prior to enrollment with FDA approved oral, intramuscular and/or intravenous chemotherapy, immunotherapy, targeted therapy, other therapy or any combination of these agents
* Patient receiving only radiation therapy
* Patient with an ECOG performance status of 2 or higher
* Patient with an expected cancer survival of less than 12 months by disease category
* Patient receiving adjuvant endocrine therapy as their only form of therapy for early-stage breast cancer
* Solid tumor patients more than 6 months post treatment and their cancer is considered to be stable or in remission as determined by the Investigator
* AZD7442 IM administration at any time prior to day of enrollment
* AZD7442 IM or IV administration on the same day as the patient receives any IV or IM cancer treatment
* Have a positive test for SARS-CoV-2 antigen performed by either Rapid Test or SARS-CoV-2 RNA by RT-PCR (Polymerase Chain Reaction) less than 90 days prior to enrollment
* Patient with a prior (within 90 days), current, or planned use of any of COVID-19 convalescent plasma, other monoclonal antibodies against SARS-CoV-2 or any other EUA approved SARS-CoV-2 treatment
* Patient with fever \>100.0 F, and/or cough, chills, loss of smell or taste or shortness of breath or any other signs or symptoms consistent with COVID-19 within 5 days prior to enrollment
* Patient who has any known active acute respiratory infection
* Patient who has persistent (refractory to treatment for ≥14 days) bacterial or fungal infection
* Patient who has a past SARS-CoV-2 infection within 90 days prior to randomization
* Patient who has received vaccination with any dose of Janssen, Pfizer or Moderna COVID-19 vaccine less than 14 days prior to baseline for this study
* Planned use of any investigational, authorized, or approved vaccine for COVID-19 less than 14 days prior to administration of AZD7442 600 mg IM or IV
* Patient who is unwilling to have SARS-CoV-2 RBD-IgG antibody levels drawn at least 3 times
* Patient who is unwilling to receive treatment with IM or IV AZD7442
* Patient who is unwilling to complete baseline and up to 13 follow-up Experience/Clinical Outcome Assessment (COA) surveys.
* Patient who is unwilling to complete baseline and up to 5 QoL assessments
* Patient who is unwilling to have blood drawn for AZD7442 serum concentration at least 9 times
* Patient who is unwilling to have blood drawn at least once for T-cell assay
* Patient whose native language is not English and does not have a person who can translate the regulatory documents, surveys and QoL assessments.
* Patient who is unable to provide Informed Consent or Authorization for Release of Health Information due to mental illness that requires a Legally Authorized Representative.
* Patient who is legally blind and does not have a witness/caregiver who has agreed to assist the patient in his/her participation in the study.
* Patient with a history of a severe allergic reaction (i.e., anaphylaxis) to any of the components of AZD7442
* Patient with a history of severe allergic reaction (hypersensitivity) to any SARS-COV-2 vaccination, Polyethylene Glycol (PEG) or Polysorbate 80
* Patient who is illiterate and does not have a witness/caregiver who has agreed to assist the patient in his/her participation in the study.
* Patient who is participating in an interventional trial for prophylaxis or treatment of SARS-CoV-2
* Absence of a qualifying type of cancer as defined by standard ICD-10 diagnostic criteria
* Treatment initiated \>12 months prior to baseline or were not on active therapy ≤12 months prior to enrollment with FDA approved oral, intramuscular and/or intravenous chemotherapy, immunotherapy, targeted therapy, other therapy or any combination of these agents
* Patient receiving only radiation therapy
* Patient with an ECOG performance status of 2 or higher
* Patient with an expected cancer survival of less than 12 months by disease category
* Patient receiving adjuvant endocrine therapy as their only form of therapy for early-stage breast cancer
* Solid tumor patients more than 6 months post treatment and their cancer is considered to be stable or in remission as determined by the Investigator
* AZD7442 IM administration at any time prior to day of enrollment
* AZD7442 IM or IV administration on the same day as the patient receives any IV or IM cancer treatment
* Have a positive test for SARS-CoV-2 antigen performed by either Rapid Test or SARS-CoV-2 RNA by RT-PCR (Polymerase Chain Reaction) less than 90 days prior to enrollment
* Patient with a prior (within 90 days), current, or planned use of any of COVID-19 convalescent plasma, other monoclonal antibodies against SARS-CoV-2 or any other EUA approved SARS-CoV-2 treatment
* Patient with fever \>100.0 F, and/or cough, chills, loss of smell or taste or shortness of breath or any other signs or symptoms consistent with COVID-19 within 5 days prior to enrollment
* Patient who has any known active acute respiratory infection
* Patient who has persistent (refractory to treatment for ≥14 days) bacterial or fungal infection
* Patient who has a past SARS-CoV-2 infection within 90 days prior to randomization
* Patient who has received vaccination with any dose of Janssen, Pfizer or Moderna COVID-19 vaccine less than 14 days prior to baseline for this study
* Planned use of any investigational, authorized, or approved vaccine for COVID-19 less than 14 days prior to administration of AZD7442 600 mg IM or IV
* Patient who is unwilling to have SARS-CoV-2 RBD-IgG antibody levels drawn at least 3 times
* Patient who is unwilling to receive treatment with IM or IV AZD7442
* Patient who is unwilling to complete baseline and up to 13 follow-up Experience/Clinical Outcome Assessment (COA) surveys.
* Patient who is unwilling to complete baseline and up to 5 QoL assessments
* Patient who is unwilling to have blood drawn for AZD7442 serum concentration at least 9 times
* Patient who is unwilling to have blood drawn at least once for T-cell assay
* Patient whose native language is not English and does not have a person who can translate the regulatory documents, surveys and QoL assessments.
* Patient who is unable to provide Informed Consent or Authorization for Release of Health Information due to mental illness that requires a Legally Authorized Representative.
* Patient who is legally blind and does not have a witness/caregiver who has agreed to assist the patient in his/her participation in the study.
* Patient with a history of a severe allergic reaction (i.e., anaphylaxis) to any of the components of AZD7442
* Patient with a history of severe allergic reaction (hypersensitivity) to any SARS-COV-2 vaccination, Polyethylene Glycol (PEG) or Polysorbate 80
* Patient who is illiterate and does not have a witness/caregiver who has agreed to assist the patient in his/her participation in the study.
* Patient who is participating in an interventional trial for prophylaxis or treatment of SARS-CoV-2
Minimum Eligible Age
18 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MediMergent, LLC
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ralph Boccia, MD
Role: PRINCIPAL_INVESTIGATOR
Center for Cancer and Blood Disorders
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Compassionate Cancer Care Medical Group
Corona, California, United States
Site Status
Compassionate Care Medical Group
Fountain Valley, California, United States
Site Status
Ventura County Hematology Oncology
Oxnard, California, United States
Site Status
Compassionate Cancer Care Medical Group
Riverside, California, United States
Site Status
Cancer Center of Southern California
Santa Monica, California, United States
Site Status
Eastern Connecticut Hematology and Oncology
Norwich, Connecticut, United States
Site Status
South Florida Cancer Care
Margate, Florida, United States
Site Status
Florida Cancer Affiliates-Ocala
Ocala, Florida, United States
Site Status
Mid-Florida Hematology Oncology Center
Orange City, Florida, United States
Site Status
Comprehensive Hematology Oncology
St. Petersburg, Florida, United States
Site Status
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Site Status
Mary Bird Perkins
Baton Rouge, Louisiana, United States
Site Status
Maryland Oncology Hematology
Annapolis, Maryland, United States
Site Status
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Site Status
Maryland Oncology Hematology
Bethesda, Maryland, United States
Site Status
Maryland Oncology Hematology
Brandywine, Maryland, United States
Site Status
Maryland Oncology Hematology
Columbia, Maryland, United States
Site Status
Maryland Oncology Hematology
Lanham, Maryland, United States
Site Status
Maryland Oncology Hematology
Rockville, Maryland, United States
Site Status
Maryland Oncology Hematology
Silver Spring, Maryland, United States
Site Status
Health Partners Institute-MMORC
Saint Louis Park, Minnesota, United States
Site Status
Oncology Hematology Associates
Springfield, Missouri, United States
Site Status
New Jersey Center for Cancer Research
Brick, New Jersey, United States
Site Status
Hunterdon Regional Cancer Center
Flemington, New Jersey, United States
Site Status
Minniti Center for Oncology and Hematology
Mickleton, New Jersey, United States
Site Status
Southeastern Medical Oncology Center
Jacksonville, North Carolina, United States
Site Status
Regional Medical Oncology Center
Wilson, North Carolina, United States
Site Status
Gabrail Cancer Center
Canton, Ohio, United States
Site Status
Zangmeister Cancer Center
Columbus, Ohio, United States
Site Status
Alliance Cancer Specialists
Bensalem, Pennsylvania, United States
Site Status
Consultants in Medical Oncology Hematology
Broomall, Pennsylvania, United States
Site Status
Pennsylvania Cancer Specialists and Research Institute
Gettysburg, Pennsylvania, United States
Site Status
Alliance Cancer Specialists
Horsham, Pennsylvania, United States
Site Status
Alliance Cancer Specialists
Langhorne, Pennsylvania, United States
Site Status
Alliance Cancer Specialists
Philadelphia, Pennsylvania, United States
Site Status
Alliance Cancer Specialists
Sellersville, Pennsylvania, United States
Site Status
Alliance Cancer Specialists
Wynnewood, Pennsylvania, United States
Site Status
Tidelands Health Oncology
Murrells Inlet, South Carolina, United States
Site Status
Carolina Blood and Cancer Care Associates
Rock Hill, South Carolina, United States
Site Status
Summit Cancer Centers
Spokane Valley, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESR 22-21698
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
NCT05426343
COMPLETED
PHASE3
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study
NCT05648110
COMPLETED
PHASE2/PHASE3
A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses
NCT03362593
TERMINATED
PHASE1
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
NCT06022224
TERMINATED
PHASE2/PHASE3
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
NCT04546581
COMPLETED
PHASE3
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
NCT04889209
COMPLETED
PHASE1/PHASE2
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
NCT04684446
COMPLETED
PHASE1/PHASE2
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
NCT04973449
COMPLETED
PHASE2/PHASE3
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
NCT05057897
TERMINATED
PHASE4
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
NCT05004181
COMPLETED
PHASE2
Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
NCT04608305
COMPLETED
PHASE1/PHASE2
A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine
NCT05442684
WITHDRAWN
PHASE3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
NCT04910269
RECRUITING
PHASE3
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
NCT05074433
TERMINATED
PHASE3
Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
NCT05249816
COMPLETED
PHASE3
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
NCT05198596
COMPLETED
PHASE3
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097
COMPLETED
PHASE2
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
NCT04614948
COMPLETED
PHASE3
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
NCT04368728
COMPLETED
PHASE2/PHASE3
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
NCT04760730
COMPLETED
PHASE1/PHASE2
Sarilumab for Patients With Moderate COVID-19 Disease
NCT04359901
COMPLETED
PHASE2
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
NCT05197153
COMPLETED
PHASE2
Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test
NCT04808921
WITHDRAWN
NA
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
NCT05011526
COMPLETED
PHASE3
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
NCT05329220
COMPLETED
PHASE3